Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if the combination of mitoxantrone,
prednisone and sorafenib will improve the time to progression of advanced stage metastatic
hormone-refractory prostate cancer.